Scirhom logo
Scirhom logo

Scirhom

scirhom.com
scirhom.com • Series A 2024 • Startup
Series A 2024 • Startup
As featured in
Yahoo Finance
markets.financialcontent.com
Bioworld
FinanzNachrichten.de
Menafn
Fierce Biotech
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$68M
1 round on record
Latest round
$68M
Series A · Jul 2024 · 2 yr ago
Backers
3
High-Tech Gründerfonds, Bayern Kapital
The money's age
Long since its last round
27 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Funding rounds
RoundDateAmountInvestorsSource
Series A Jul 2024 $68M — FinanzNachrichten.de
Backed byfrom the funds' portfolios and accelerator catalogs
High-Tech Gründerfonds fund Bayern Kapital fund Kurma Partners fund

News

News YahooFinance 2 years ago
SciRhom pulls in $70M for a new type of immune disease drug
The Series A round will help the startup bring its lead candidate, an antibody aimed at the proteiniRhom2, into human testing by the end of 2024.
Read more
Report
News YahooFinance 2 years ago
SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases
SciRhom Leadership Team (2024) From left to right: Dr. Jens Ruhe, Managing Director and Chief Operating Officer - Dr. Jan Poth, Managing Director and Chief Executive Officer - Dr. Matthias Schneider, Chief Scientific Officer ( SciRhom, taken by Paul Pauls
Read more
Report
News markets.financialcontent.com 2 years ago
SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases
SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases
Read more
Report
News bioworld.com 2 years ago
Scirhom targeting iRhom2 in autoimmune disease with €63M series A Read more
Report
News FinanzNachrichten.de 2 years ago
SciRhom GmbH: SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2
Read more
Report
News menafn.com 2 years ago
MIG Capital Co-Leads €63 Million Series A Round For Autoimmune Biotech Scirhom Read more
Report
News fiercebiotech.com 4 years ago
After 20 years, Boehringer vet hits the exit to become CEO at autoimmune biotech SciRhom Read more
Report

Financials

Total raised
$68M
Latest round
Series A
Funding rounds
1
Funding rounds
Round Announced Amount
Series A 2024 $68M Details